• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Imatron expects record 1994 revenues

Article

CT developer Imatron is anticipating record revenues for its 1994fiscal year (end-December). The South San Francisco, CA, companysaid last week that its revenues for the year should exceed $33million, an increase of at least 31% over last year's figure

CT developer Imatron is anticipating record revenues for its 1994fiscal year (end-December). The South San Francisco, CA, companysaid last week that its revenues for the year should exceed $33million, an increase of at least 31% over last year's figure of$25.1 million. Net income for 1994 should be $2.3 million, versusa loss of $2.9 million in 1993.

Imatron has enjoyed strong sales of its C-150 Ultrafast CTscanner in recent months. Imatron received an order in Decemberfor 10 C-150 units from Imatron Japan in a transaction worth $16million (SCAN 12/28/94). Revenue from that sale will registerin the company's 1995 and 1996 fiscal years.

Imatron's backlog is at its highest level since the companywas formed in 1983, president and CEO Lewis Meyer said. The backlogshould help the firm register revenues of over $40 million in1995.

This year Imatron will embark on a major expansion of its HeartScanImaging clinics, which provide coronary artery screening directlyto the public (SCAN 4/6/94). Imatron plans to open clinics inSeattle, Houston and Washington, DC.

Related Videos
Emerging Research at SNMMI Examines 18F-flotufolastat in Managing Primary and Recurrent Prostate Cancer
Could Pluvicto Have a Role in Taxane-Naïve mCRPC?: An Interview with Oliver Sartor, MD
New SNMMI President Cathy Cutler, PhD, Discusses Current Challenges and Goals for Nuclear Medicine
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Related Content
© 2024 MJH Life Sciences

All rights reserved.